PCV10和PCV13对6C型肺炎链球菌疾病、携带及抗菌药物耐药的影响
该系统评价纳入112项研究,评估PCV10和PCV13对6C型肺炎链球菌侵袭性疾病、非侵袭性疾病、鼻咽携带及抗菌药物耐药的直接、间接和总体效果。PCV13对儿童6C型侵袭性疾病有持续保护,PCV10无保护,且6C型疾病在PCV10后增加;作者建议疫苗决策者考虑含6A血清型PCV对6C型疾病的效果。
要点
- PCV13全程接种儿童对6C型侵袭性肺炎链球菌病的疫苗有效性为94%(n=2项研究)。
- ≥1剂PCV13对儿童6C型侵袭性肺炎链球菌病的直接疫苗有效性为70%至85%(n=3项研究)。
- PCV10后6C型侵袭性和非侵袭性疾病在所有研究(n=6/6)中均增加。
核心结论
- 与PCV10不同,PCV13在儿童中持续保护6C型侵袭性肺炎链球菌病和鼻咽携带,并对成人提供一定程度的间接保护,支持6A而非6B血清型对6C提供交叉保护。
- 作者建议疫苗政策制定者和监管者在决策中考虑含6A血清型PCV对6C型疾病的效果。
研究设计与样本
- 系统综述,检索Medline和Embase中2010年1月至2022年8月发表的随机对照试验和观察性研究。
- 共识别2548篇文献,最终纳入112篇,覆盖PCV10和PCV13对6C型侵袭性肺炎链球菌病、非侵袭性疾病、鼻咽携带及抗菌药物耐药的直接、间接和总体效果。
主要发现
- ≥1剂PCV13对儿童6C型侵袭性肺炎链球菌病的直接疫苗有效性为70%至85%(n=3项研究),全程PCV13接种儿童为94%(n=2项研究)。
- ≥1剂PCV10对儿童6C型侵袭性肺炎链球菌病的直接疫苗有效性为-14%(n=1项研究)。
- 与PCV7相比,PCV13对儿童6C型鼻咽携带的效力为66%(n=1项研究)。
- PCV13后6C型侵袭性肺炎链球菌病发病率或鼻咽携带率在多数儿童研究(n=5/6)和近半数成人研究(n=5/11)中下降。
- PCV10后6C型侵袭性和非侵袭性疾病在所有研究(n=6/6)中均增加,抗菌药物耐药流行变化不一致。
关键数值与推荐
- 直接疫苗有效性:≥1剂PCV13对儿童6C型侵袭性肺炎链球菌病为70%至85%(n=3项研究),全程PCV13接种为94%(n=2项研究),≥1剂PCV10为-14%(n=1项研究)。
- PCV13对儿童6C型鼻咽携带的效力相较于PCV7为66%(n=1项研究)。
- PCV13后6C型侵袭性肺炎链球菌病发病率或鼻咽携带率下降见于儿童研究n=5/6、成人研究n=5/11。
- PCV10后6C型侵袭性和非侵袭性疾病增加见于所有研究(n=6/6)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The cross-protection of pneumococcal conjugate vaccines (PCV) against serotype 6C is not clearly documented, although 6C represents a substantial burden of pneumococcal disease in recent years. A systematic review by the World Health Organization that covered studies through 2016 concluded that available data were insufficient to determine if either PCV10 (which contains serotype 6B but not 6A) or PCV13 (containing serotype 6A and 6B) conferred protection against 6C. METHODS: We performed a systematic review of randomized controlled trials and observational studies published between January 2010 - August 2022 (Medline/Embase), covering the direct, indirect, and overall effect of PCV10 and PCV13 against 6C invasive pneumococcal disease (IPD), non-IPD, nasopharyngeal carriage (NPC), and antimicrobial resistance (AMR). RESULTS: Of 2548 publications identified, 112 were included. Direct vaccine effectiveness against 6C IPD in children ranged between 70 and 85 % for ≥ 1 dose PCV13 (n = 3 studies), was 94 % in fully PCV13 vaccinated children (n = 2), and -14 % for ≥ 1 dose of PCV10 (n = 1). Compared to PCV7, PCV13 efficacy against 6C NPC in children was 66 % (n = 1). Serotype 6C IPD rates or NPC prevalence declined post-PCV13 in most studies in children (n = 5/6) and almost half of studies in adults (n = 5/11), while it increased post-PCV10 for IPD and non-IPD in all studies (n = 6/6). Changes in AMR prevalence were inconsistent. CONCLUSIONS: In contrast to PCV10, PCV13 vaccination consistently protected against 6C IPD and NPC in children, and provided some level of indirect protection to adults, supporting that serotype 6A but not 6B provides cross-protection to 6C. Vaccine policy makers and regulators should consider the effects of serotype 6A-containing PCVs against serotype 6C disease in their decisions.
引用
- Grant LR, Hanquet G, Sepúlveda-Pachón IT, et al. Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance. Vaccine. 2024. PMID: 38553292. doi:10.1016/j.vaccine.2024.03.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。